Tags : Radioligand Pipeline


Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology

Shots: Novartis gets an exclusive WW right to develop and commercialize therapeutic applications for FAP assets including FAPI-46 and FAPI-74 under its collaboration with iTheranostics, which is an affiliate of SOFIE Biosciences The agreement also consists of co-exclusive rights for Novartis to develop imaging applications for FAP assets The company will continue to reimagine cancer […]Read More